Captrust Financial Advisors Adaptimmune Therapeutics PLC Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Captrust Financial Advisors holds 83,041 shares of ADAP stock, worth $83,871. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,041
Previous 111,952
25.82%
Holding current value
$83,871
Previous $176,000
53.98%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ADAP
# of Institutions
81Shares Held
152MCall Options Held
78.5KPut Options Held
36.5K-
Matrix Capital Management Company, LP Waltham, MA39MShares$39.4 Million0.29% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$27.7 Million0.95% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$17.3 Million1.58% of portfolio
-
Baillie Gifford & CO15.1MShares$15.3 Million0.01% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR12.3MShares$12.5 Million0.49% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $165M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...